RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Robert Kirken to Interleukin-2

This is a "connection" page, showing publications Robert Kirken has written about Interleukin-2.
Connection Strength

4.440
  1. Estrada A, Rodriguez AC, Rodriguez G, Grant AH, Ayala-Marin YM, Arrieta AJ, Kirken RA. Phosphorylation of CrkL S114 induced by common gamma chain cytokines and T-cell receptor signal transduction. Sci Rep. 2021 08 20; 11(1):16951.
    View in: PubMed
    Score: 0.768
  2. Ruiz-Medina BE, Cadena-Medina DA, Esparza E, Arrieta AJ, Kirken RA. Isoproterenol-induced beta-2 adrenergic receptor activation negatively regulates interleukin-2 signaling. Biochem J. 2018 09 18; 475(18):2907-2923.
    View in: PubMed
    Score: 0.627
  3. Ruiz-Medina BE, Ross JA, Kirken RA. Interleukin-2 Receptor ? Thr-450 Phosphorylation Is a Positive Regulator for Receptor Complex Stability and Activation of Signaling Molecules. J Biol Chem. 2015 Aug 21; 290(34):20972-20983.
    View in: PubMed
    Score: 0.502
  4. Nagy ZS, Ross JA, Rodriguez G, Balint BL, Szeles L, Nagy L, Kirken RA. Genome wide mapping reveals PDE4B as an IL-2 induced STAT5 target gene in activated human PBMCs and lymphoid cancer cells. PLoS One. 2013; 8(2):e57326.
    View in: PubMed
    Score: 0.427
  5. Behbod F, Nagy ZS, Stepkowski SM, Karras J, Johnson CR, Jarvis WD, Kirken RA. Specific inhibition of Stat5a/b promotes apoptosis of IL-2-responsive primary and tumor-derived lymphoid cells. J Immunol. 2003 Oct 15; 171(8):3919-27.
    View in: PubMed
    Score: 0.223
  6. Grant AH, Rodriguez AC, Rodriguez Moncivais OJ, Sun S, Li L, Mohl JE, Leung MY, Kirken RA, Rodriguez G. JAK1 Pseudokinase V666G Mutant Dominantly Impairs JAK3 Phosphorylation and IL-2 Signaling. Int J Mol Sci. 2023 Apr 06; 24(7).
    View in: PubMed
    Score: 0.215
  7. Nagy ZS, Wang Y, Erwin-Cohen RA, Aradi J, Monia B, Wang LH, Stepkowski SM, Rui H, Kirken RA. Interleukin-2 family cytokines stimulate phosphorylation of the Pro-Ser-Pro motif of Stat5 transcription factors in human T cells: resistance to suppression of multiple serine kinase pathways. J Leukoc Biol. 2002 Oct; 72(4):819-28.
    View in: PubMed
    Score: 0.207
  8. Stepkowski SM, Kirken RA. The role of IL-2 in allograft rejection--a lesson learned from experimental work. Transplantation. 2000 Jun 27; 69(12):2480-2.
    View in: PubMed
    Score: 0.177
  9. Kirken RA, Malabarba MG, Xu J, DaSilva L, Erwin RA, Liu X, Hennighausen L, Rui H, Farrar WL. Two discrete regions of interleukin-2 (IL2) receptor beta independently mediate IL2 activation of a PD98059/rapamycin/wortmannin-insensitive Stat5a/b serine kinase. J Biol Chem. 1997 Jun 13; 272(24):15459-65.
    View in: PubMed
    Score: 0.144
  10. Kirken RA, Rui H, Evans GA, Farrar WL. Characterization of an interleukin-2 (IL-2)-induced tyrosine phosphorylated 116-kDa protein associated with the IL-2 receptor beta-subunit. J Biol Chem. 1993 Oct 25; 268(30):22765-70.
    View in: PubMed
    Score: 0.112
  11. Rodriguez G, Ross JA, Nagy ZS, Kirken RA. Forskolin-inducible cAMP pathway negatively regulates T-cell proliferation by uncoupling the interleukin-2 receptor complex. J Biol Chem. 2013 Mar 08; 288(10):7137-46.
    View in: PubMed
    Score: 0.106
  12. Nagy ZS, Ross JA, Rodriguez G, Bader J, Dimmock J, Kirken RA. Uncoupling JAK3 activation induces apoptosis in human lymphoid cancer cells via regulating critical survival pathways. FEBS Lett. 2010 Apr 16; 584(8):1515-20.
    View in: PubMed
    Score: 0.087
  13. Ross JA, Cheng H, Nagy ZS, Frost JA, Kirken RA. Protein phosphatase 2A regulates interleukin-2 receptor complex formation and JAK3/STAT5 activation. J Biol Chem. 2010 Feb 05; 285(6):3582-3591.
    View in: PubMed
    Score: 0.085
  14. Nagy ZS, LeBaron MJ, Ross JA, Mitra A, Rui H, Kirken RA. STAT5 regulation of BCL10 parallels constitutive NFkappaB activation in lymphoid tumor cells. Mol Cancer. 2009 Aug 26; 8:67.
    View in: PubMed
    Score: 0.084
  15. Cheng H, Ross JA, Frost JA, Kirken RA. Phosphorylation of human Jak3 at tyrosines 904 and 939 positively regulates its activity. Mol Cell Biol. 2008 Apr; 28(7):2271-82.
    View in: PubMed
    Score: 0.075
  16. Nagy ZS, Rui H, Stepkowski SM, Karras J, Kirken RA. A preferential role for STAT5, not constitutively active STAT3, in promoting survival of a human lymphoid tumor. J Immunol. 2006 Oct 15; 177(8):5032-40.
    View in: PubMed
    Score: 0.069
  17. Stepkowski SM, Kao J, Wang ME, Tejpal N, Podder H, Furian L, Dimmock J, Jha A, Das U, Kahan BD, Kirken RA. The Mannich base NC1153 promotes long-term allograft survival and spares the recipient from multiple toxicities. J Immunol. 2005 Oct 01; 175(7):4236-46.
    View in: PubMed
    Score: 0.064
  18. Qu X, Kirken RA, Tian L, Wang M, Bennett CF, Stepkowski SM. Selective inhibition of IL-2 gene expression by IL-2 antisense oligonucleotides blocks heart allograft rejection. Transplantation. 2001 Sep 15; 72(5):915-23.
    View in: PubMed
    Score: 0.048
  19. Behbod F, Erwin-Cohen RA, Wang ME, Trawick BW, Qu X, Verani R, Kahan BD, Stepkowski SM, Kirken RA. Concomitant inhibition of Janus kinase 3 and calcineurin-dependent signaling pathways synergistically prolongs the survival of rat heart allografts. J Immunol. 2001 Mar 15; 166(6):3724-32.
    View in: PubMed
    Score: 0.047
  20. Kirken RA, Erwin-Cohen R, Behbod F, Wang M, Stepkowski SM, Kahan BD. Tyrphostin AG490 selectively inhibits activation of the JAK3/STAT5/MAPK pathway and rejection of rat heart allografts. Transplant Proc. 2001 Feb-Mar; 33(1-2):95.
    View in: PubMed
    Score: 0.046
  21. Tian L, Qu X, Wang ME, Kirken RA, Bennett FC, Stepkowski SM. Selective inhibition of IL-2 mRNA blocks allograft rejection by limiting T cell clonal expansion. Transplant Proc. 2001 Feb-Mar; 33(1-2):330.
    View in: PubMed
    Score: 0.046
  22. Yen CH, Yang YC, Ruscetti SK, Kirken RA, Dai RM, Li CC. Involvement of the ubiquitin-proteasome pathway in the degradation of nontyrosine kinase-type cytokine receptors of IL-9, IL-2, and erythropoietin. J Immunol. 2000 Dec 01; 165(11):6372-80.
    View in: PubMed
    Score: 0.046
  23. Kirken RA, Erwin RA, Wang L, Wang Y, Rui H, Farrar WL. Functional uncoupling of the Janus kinase 3-Stat5 pathway in malignant growth of human T cell leukemia virus type 1-transformed human T cells. J Immunol. 2000 Nov 01; 165(9):5097-104.
    View in: PubMed
    Score: 0.045
  24. Kirken RA, Erwin RA, Taub D, Murphy WJ, Behbod F, Wang L, Pericle F, Farrar WL. Tyrphostin AG-490 inhibits cytokine-mediated JAK3/STAT5a/b signal transduction and cellular proliferation of antigen-activated human T cells. J Leukoc Biol. 1999 Jun; 65(6):891-9.
    View in: PubMed
    Score: 0.041
  25. Kirken RA, Evans GA, Duh? RJ, DaSilva L, Malabarba MG, Erwin RA, Farrar WL. Mechanisms of cytokine signal transduction: IL-2, IL-4 and prolactin as hematopoietin receptor models. Vet Immunol Immunopathol. 1998 May 15; 63(1-2):27-36.
    View in: PubMed
    Score: 0.038
  26. Pericle F, Kirken RA, Epling-Burnette PK, Blanchard DK, Djeu JY. Direct killing of interleukin-2-transfected tumor cells by human neutrophils. Int J Cancer. 1996 May 03; 66(3):367-73.
    View in: PubMed
    Score: 0.033
  27. Kirken RA, Rui H, Malabarba MG, Farrar WL. Identification of interleukin-2 receptor-associated tyrosine kinase p116 as novel leukocyte-specific Janus kinase. J Biol Chem. 1994 Jul 22; 269(29):19136-41.
    View in: PubMed
    Score: 0.029
  28. Johnston JA, Kawamura M, Kirken RA, Chen YQ, Blake TB, Shibuya K, Ortaldo JR, McVicar DW, O'Shea JJ. Phosphorylation and activation of the Jak-3 Janus kinase in response to interleukin-2. Nature. 1994 Jul 14; 370(6485):151-3.
    View in: PubMed
    Score: 0.029
  29. Wang LH, Kirken RA, Erwin RA, Yu CR, Farrar WL. JAK3, STAT, and MAPK signaling pathways as novel molecular targets for the tyrphostin AG-490 regulation of IL-2-mediated T cell response. J Immunol. 1999 Apr 01; 162(7):3897-904.
    View in: PubMed
    Score: 0.010
  30. Yu CR, Kirken RA, Malabarba MG, Young HA, Ortaldo JR. Differential regulation of the Janus kinase-STAT pathway and biologic function of IL-13 in primary human NK and T cells: a comparative study with IL-4. J Immunol. 1998 Jul 01; 161(1):218-27.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support